**Table 2.** Clinical characteristics

|  |  |  |
| --- | --- | --- |
|  | **Survey responders****N = 83** | **ENLIVEN patients\*****N = 120** |
| **Time from TGCT diagnosis to initiation of pexidartinib (years)**  |  |  |
| Mean (SD), median | 5.4 (4.6), 4.0 | 5.3 (6.8), 3.5 |
| **Disease location, n (%)** |  |  |
| Lower extremities |  |  |
| Knee | 51 (61.4) | 73 (60.8) |
| Ankle | 10 (12.0) | 21 (17.5) |
| Hip | 10 (12.0) | 13 (10.8) |
| Foot | 7 (8.4) | 3 (2.5) |
| Upper extremities |  |  |
| Wrist | 3 (3.6) | 4 (3.3) |
| Hand/finger | 3 (3.6) | 1 (0.8) |
| Elbow | 2 (2.4) | 1 (0.8) |
| Shoulder | 2 (2.4) | 2 (1.7) |
| Spine | N/A | 2 (1.7) |
| **Previous surgeries for TGCT, n (%)** |  |  |
| 0 | 21 (25.3) | 57 (47.5) |
| 1 | 22 (26.5) | 25 (20.8) |
| 2  | 15 (18.1) | 19 (15.8) |
| ≥ 3 | 25 (30.1) | 19 (15.8) |
| **Previous systemic therapy** |  |  |
| No previous systemic therapy | 63 (75.9) | 109 (90.8) |
| Imatinib | 17 (20.5) | 10 (8.3) |
| Nilotinib | 1 (1.2) |  1 (0.8) |

\* Tap WD, et al. *Lancet*. 2019;394:478-487.